Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06041646 · ClinicalTrials.gov registry record · Phase 4
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
A Phase 4 study, sponsored by BioXcel Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT06041646 is a Phase 4 study that has completed, run by BioXcel Therapeutics. The registered enrollment target is 29 participants.
The verdict
NCT06041646, a Phase 4 study, has completed, sponsored by BioXcel Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
Interventions
- DRUG Sublingual film containing Igalmi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2024-04-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06041646
The ClinicalTrials.gov registry entry for NCT06041646 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioXcel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sublingual film containing Igalmi is the first listed.
NCT06041646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06041646 about?
NCT06041646 is a clinical study titled "Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder". This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
What is the current status of trial NCT06041646?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2023-10-02. Estimated completion is 2024-04-29.
What interventions are being tested in trial NCT06041646?
The interventions under investigation include: Sublingual film containing Igalmi (DRUG).
Who is sponsoring clinical trial NCT06041646?
This trial is sponsored by BioXcel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.